XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
  UK
   NHS
  USA
  World
  India
  South Africa
  New Zealand
  Australia
  Canada Healthcare
  China Healthcare
  Africa
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

UK Channel
subscribe to UK newsletter

Medical News : Healthcare : UK

   DISCUSS   |   EMAIL   |   PRINT
Old age psychiatrists join to oppose 'NICE' proposal to withdraw Alzheimer's treatments from NHS
Mar 18, 2005, 16:02, Reviewed by: Dr.

"We hope that psychiatrists, carers and relatives of people with AD will make their views known to NICE and to their MPs, so that the conclusions of this draft guidance are changed to enable patients with AD to continue to benefit from the drugs currently prescribed under the NHS"

 
The Royal College of Psychiatrists' Faculty of Old Age Psychiatry, with more than 1,800 members across the country, has drawn up a new Resolution which says that denying people with Alzheimer's disease (AD) access to the drugs used to treat the condition will have a detrimental effect on their health and life.

On March 1st 2005 the National Institute of Clinical Excellence (NICE) published their Appraisal Consultation Document, which concluded that the drugs currently used to treat mild to moderate AD (cholinesterase inhibitors) are not cost-effective and should not therefore be available on the NHS.

The unanimously agreed Resolution from the Faculty of Old Age Psychiatry strongly disagrees with the assumptions and methodology of the health economic analysis that led NICE to these conclusions.

'The Faculty's opinion is that denying people with AD access to these drugs will have a detrimental effect on the health and lives of patients and their carers, and on services as a whole," the Resolution states.

A letter sent to Faculty members urges them to draw to NICE's attention a number of weaknesses in their analysis of the data, including the facts that:

* traditional ways of measuring quality of life are not valid in AD
* NICE's previous (2001) appraisal of these drugs accepted problems with the use of quality of life measures in AD
* the economic modelling used in NICE's analysis is not realistic i.e. not based on the use of the drugs in clinical practice
* the guidance ignores, or totally underestimates, the wider societal implications that NICE is obliged to take into account
* alternative treatments (e.g. antipsychotics drugs) will actively do harm.

In addition to responding to NICE, Faculty members will be writing to their MPs.

Prof. Susan Benbow, Chair of the Faculty of Old Age Psychiatry, commented, 'We are all very concerned by the implications for our patients of this new advice. In this consultation paper NICE seems to have adopted an inconsistent and contradictory approach that bears little resemblance to the guidance they issued in 2001.

'NICE agrees that the drugs currently used to treat AD are clinically effective. But the evidence on which they conclude that cholinesterase inhibitors are not cost effective is, we strongly believe, flawed.

'We hope that psychiatrists, carers and relatives of people with AD will make their views known to NICE and to their MPs, so that the conclusions of this draft guidance are changed to enable patients with AD to continue to benefit from the drugs currently prescribed under the NHS."
 

- The Royal College of Psychiatrists Website
 

http://www.rcpsych.ac.uk

 
Subscribe to UK Newsletter
E-mail Address:

 

The following resolution was passed at the Faculty of Old Age Psychiatry Conference on 4th March 2005.

RESOLUTION

* The Faculty of Old Age Psychiatry welcomes the conclusions of NICE in its Appraisal Consultation Document that the cholinesterase inhibitors are clinically effective for people with Alzheimer's Disease.

* However the Faculty disagrees with the assumptions and methodology of the health economic analysis that has led NICE to conclude that these drugs are not cost effective.

* The Faculty's opinion is that denying people with AD access to these drugs will have a detrimental effect on the health and lives of patients and their carers, and on services as a whole.

9th March 2004


Related UK News

Indians among worst affected by TB in Britain
Mental health units should not be exempt from smoking ban
NHS may be buying surgical equipment unethically
Is it time to give NHS more independence?
University of Leeds receives Gates Foundation grant for material approach to malaria prevention
Tuberculosis control and impact of socially excluded groups
Pertussis Endemic Among UK School Children
Building a safer NHS: How safe are the patients?
Experts Comment on New Blood Pressure Guidelines
New Guideance will Result in Better Control of Hypertension - BPA


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us